The interaction between serum endostatin , estimated glomerular filtration rate ( eGFR ) and predefined endpoints , including the primary endpoint ( CV death , nonfatal myocardial infarction , nonfatal stroke ; n = @ ) , all-cause mortality ( n = @ ) , CV death ( n = @ ) or the coronary endpoint ( n = @ ) , was evaluated in @,@ patients > @ years of age with ischemic systolic HF in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) population , who were randomly assigned to @ mg rosuvastatin or placebo .